THRB and metabolic dysfunction-associated steatohepatitis: The U.S. Food and Drug Administration (FDA) just approved the first drug, Madrigal’s resmetirom, an oral liver-targeted thyroid hormone receptor-beta (THRβ) agonist, for treating NASH (the term used by the FDA to describe this condition) [14].